Smart Money Circle

This Biotech CEO Is Helping Prevent Surgical Infections – Meet Dikla Czaczkes Akselbrad, CEO PolyPid $PYPD

Guest

Dikla Czaczkes Akselbrad, CEO PolyPid

Company

PolyPid

https://www.polypid.com/

Ticker: $PYPD

Dikla’s Bio

Ms. Dikla Czaczkes Akselbrad serves as the Chief Executive Officer of PolyPid after serving as the company’s EVP and CFO since 2017, leading the company’s initial public offering on the Nasdaq Global Market in June 2020.

Dikla brings more than 20 years of experience leading life sciences companies through critical international strategic, financial and business transitions, including raising over $350 million in various forms in her prior executive roles.

Before joining PolyPid in 2014, Dikla served as CFO of Compugen Ltd. (NASDAQ & TASE: CGEN) after serving as CFO of Packet Technologies Ltd., and an audit manager at Ernst & Young Israel. She received a B.A. in accounting and economics and an MBA from Tel-Aviv University, and is a certified public accountant in Israel.

Guest:

Martin Brenner, Ph.D., Chief Executive Officer and Chief Scientific Officer at iBio

Company: iBio, Inc. (NASDAQ:IBIO)

Website:

https://ibioinc.com/

Martin’s Bio:

Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world’s leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020.

Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need.

Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team’s research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca.

In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.

Company Description:

iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Guest

Steve Salis

Founder, Entrepreneur, Investor, Executive

Websites

https://salis.com/

https://catalogue.co/

https://22realestateholdings.com/

https://sizzlespac.com/home/default.aspx

Bio

Steve Salis has always had an inherent ability to make the everyday exceptional. His early entrepreneurial spirit led him to drop out of college to “get a head start on his life”. His intuitive knowledge on how to develop, build and invest in dynamic brands that deeply connect with consumers led him to co-founding &pizza, an east coast, regionally-based pizza chain, from the ground up to approximately 60 stores in 5 states and DC, which he subsequently sold in 2019.

Today, Steve continues his growth trajectory as the owner of Salis Holdings, a Washington, D.C based family office and diversified holding company with interests in hospitality, consumer, leisure, retail, real estate, venture and other sectors. Salis Holdings has frequently been mentioned as one of the fastest growing organizations in the Mid-Atlantic region. Steve founded and is CEO of a consumer platform called Catalogue, which includes many highly recognized brands in the Mid-Atlantic region including Ted’s Bulletin, Kramerbooks, Honeymoon Chicken and Federalist Pig.

In addition to Steve’s private holdings, he is also the Chairman and CEO of the Sizzle Acquisition Corp franchise. In early 2024, Sizzle Acquisition Corp I merged with European Lithium to form Critical Metals Corp (CRML) which owns the largest rare earth project in Europe and currently has a market cap of over $2.0b. Steve launched Sizzle Acquisition Corp II (SZZL) in April of 2025 raising 230MM to acquire another company.

In addition, Steve has a growing portfolio of commercial and mixed-use real estate assets in Washington, DC, Virginia and Maryland under 22 Real Estate Holdings.

Throughout his career, Steve has created strong cultural identities around the brands he's founded, invested, acquired, and led. He embodies the hustle, grit, talent, and acumen to build an empire of multi-faceted businesses destined for success.

Guest

Ryan King serves as Executive Vice President, Capital Markets and Strategy at Equinox Gold.

Company Name and Symbol:

Equinox Gold Corp. (NYSE: EQX, TSX: EQX)

Website:

https://www.equinoxgold.com/

Ryan’s Bio:

Ryan King serves as Executive Vice President, Capital Markets and Strategy at Equinox Gold, where he plays a key role in the company's strategic initiatives and capital market activities. He has been instrumental in leading the strategic merger with Calibre Mining, which has positioned the combined entity as a major force in North American gold production. With extensive experience in capital markets and strategic planning, Ryan brings deep expertise in mergers and acquisitions, investor relations, and corporate development to his role at one of the Americas' leading gold producers.

Company Bio:

Equinox Gold has transitioned into a financially stronger, North America-focused gold producer. With Greenstone ramping up and Valentine now in commercial production, two cornerstone Canadian assets are driving meaningful growth. After delivering record 2025 production of 922,827 ounces, 2026 guidance represents an 80% increase in annual Canadian gold production. At the same time, the Brazil spin-off for $1.015 billion has strengthened the company’s balance sheet and sharpened strategic focus.

Guest Name: Justin Stiefel, Chairman & Chief Executive Officer, IP Strategy

Company IP Strategy

Website: https://ipstrategy.co/

Ticker: $IPST

Justin's Bio:

Justin is the CEO of IP Strategy and a seasoned attorney and engineer with extensive leadership experience across both business and government. Before that, he served as Chief of Staff in the United States Senate, bringing a strong background in regulation, policy, and operations.

Company Name & Bio:

IP Strategy's Bio:

(Nasdaq: IPST) is the first Nasdaq-listed company to hold $IP tokens as a primary reserve asset and operate a validator for the Story Network. The Company provides public market investors broad exposure to the $80 trillion programmable intellectual property economy in a regulated equity format. IP Strategy’s treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property. Heritage Distilling Holding Company, Inc. is the registered corporate name of IP Strategy.

This CEO Is Using Ocean Waves To Generate Power – Meet Inna Braverman Founder & CEO of Eco Wave Power $WAVE

Guest:

Inna Braverman, Founder & CEO of Eco Wave Power (NASDAQ: WAVE)

Company:

Eco Wave Power (NASDAQ: WAVE)

Website

https://www.ecowavepower.com/

Inna’s Bio

Inna Braverman founded Eco Wave Power at the age of 24, pioneering innovative wave energy technology. Under her leadership, the company installed the first grid-connected wave energy array in Israel, has secured a significant project pipeline of 404.7 MW, and is expanding globally. In July 2021, she led Eco Wave Power’s IPO on Nasdaq Capital Market (WAVE), marking a major milestone for the company and the wave energy sector.

Recognized as a global leader in renewable energy, Inna has been named one of the “Females Changing the World” by Wired Magazine and one of the “Most Creative People in Business” by Fast Company. She is also a recipient of the United Nations Global Climate Action Award.

For Inna, clean energy is personal. Born two weeks before the Chernobyl Nuclear Disaster, she suffered respiratory arrest due to pollution. Her mother, a nurse, saved her life with mouth-to-mouth resuscitation. This second chance inspired her to dedicate her life to developing a clean and safe method of electricity generation.

Company Bio

Eco Wave Power Global (NASDAQ: WAVE) is a pioneering onshore wave energy company that transforms the power of ocean and sea waves into clean, reliable, and cost-efficient electricity through its patented, intelligent technology.

With a mission to accelerate the global transition to renewable energy, Eco Wave Power developed and operates Israel’s first grid-connected wave energy power station, recognized as a “Pioneering Technology” by the Israeli Ministry of Energy and co-funded by EDF Renewables IL. In the United States, the company recently launched the first-ever onshore wave energy pilot station at the Port of Los Angeles, in collaboration with Shell Marine Renewable Energy (Shell MRE)

Eco Wave Power is expanding rapidly worldwide, with upcoming projects in Portugal, Taiwan, and India, representing a robust project pipeline of 404.7 MW under development. The company has received international recognition and support from organizations including the European Union Regional Development Fund, Innovate UK, and the EU Horizon 2020 program, and was honored with the United Nations Global Climate Action Award.

Eco Wave Power’s American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market under the ticker symbol “WAVE.”

Guest

Mike Logozzo is the Chief Executive Officer of reAlpha Tech Corp.

Ticker:

$AIRE

Website

https://www.realpha.com/mortgage

Company Bio

About reAlpha reAlpha Tech Corp. (Nasdaq: AIRE) is an AI-driven real estate technology company redefining how Americans buy homes. Headquartered in Dublin, Ohio, reAlpha is building an end-to-end, commission-free platform that integrates real estate brokerage, mortgage and title services into one seamless experience. By combining proprietary AI capabilities with a strategic, acquisition-led growth model, the company is creating a vertically integrated ecosystem that reduces costs, increases efficiency, and accelerates access to homeownership. Targeting the multi-trillion-dollar U.S. real estate services market, reAlpha aims to provide consumers with a smarter, faster, and more affordable path to buying a home, while setting a new standard for real estate innovation.

CEO Bio

Mike Logozzo - Chief Executive Officer Mike Logozzo is the Chief Executive Officer of reAlpha Tech Corp., where he leads operations, strategy, and delivery across the company’s real estate technology platform. With more than two decades of experience, he has built a career at the intersection of financial services, technology, and innovation. He previously managed a $32 billion portfolio serving 1.2 million customers at BMW Financial Services, drove global operational efficiency at Microsoft, and advanced corporate innovation as Managing Director at L Marks, helping multinational enterprises accelerate adoption of emerging technologies. This combination of financial stewardship, operational excellence, and innovation leadership defines his approach to scaling businesses and creating long-term value for stakeholders.

This Biotech Stock Is Disrupting Cancer Treatment - Meet Raphi Levy, CFO, Alpha Tau

$DRTS

Guest

Raphi Levy, CFO, Alpha Tau

Company

Alpha Tau

Ticker: $DRTS

Website https://www.alphatau.com

Raphi's Bio

Raphi Levy has served as our Chief Financial Officer since 2019. Prior to joining us, Mr. Levy served in the Investment Banking Division at Goldman Sachs from 2006 until 2019 in New York and Tel Aviv, most recently serving as Executive Director in charge of healthcare banking in Israel.

Mr. Levy has served as a director of MX Management LP since April 2022. Mr. Levy holds a B.S. in Economics from the Wharton School of Business, University of Pennsylvania, and a B.S.E. and M.S.E. in Electrical Engineering from the School of Engineering and Applied Science, University of Pennsylvania.

Company Bio

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Guest Full Name: Dr. R. Stacy Lindborg, PhD

Guest Title: President, Chief Executive Officer, and Board Director

Company: IMUNON

Ticker: IMNN

Website: https://imunon.com/

Guest Bio:

Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of IMUNON in May 2024. Dr. Lindborg has served on IMUNON’s Board of Directors since June 2021. She has nearly 30 years of experience in the pharmaceutical and biotech industries, with a particular focus on R&D, regulatory affairs, executive management, and strategy development. She has designed, hired, and led global teams, guiding long-term visions for growth through analytics and stimulating innovative development platforms to increase productivity.

Prior to joining IMUNON, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics, where she remains a member of the company’s Board of Directors. At BrainStorm, she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She frequently interacted with investors and analysts, represented the company in the scientific community and with the media, and played an active role in discussions with potential business partners.

Dr. Lindborg previously was Vice President and Head of Global Analytics and Data Sciences, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company, where, over the course of 16 years, she assumed positions of increasing responsibility, including Head of R&D strategy.

Dr. Lindborg received an MA and PhD in statistics, and a BA in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.

Company Bio:

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of diseases. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 is the first therapy to achieve a clinically effective response in advanced (stage IIIC/IV) ovarian cancer including benefits in both progression-free survival (PFS) and overall survival (OS) in a first-line treatment setting when used with standard of care chemotherapy. IMUNON has completed multiple clinical trials evaluating the potential of IMNN-001, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). The first patient was dosed in the Phase 3 study in the third quarter of 2025. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as IL-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Guest

Darren Wang, Founder & Chairman at OwlTing Group

Company: OwlTing Group

Ticker: OWLS

Website:

https://www.owlting.com/portal/?lang=en

Bio

With a background in cryptography with prior experience at tech companies in Silicon Valley, Darren founded OwlTing in 2010 to leverage blockchain technology to connect the world and drive industry transformation; today, OwlTing’s core focus is building compliant stablecoin infrastructure for the future through OwlPay, advancing global payment and settlement capabilities for enterprises and platforms. The group also operates broader enterprise and consumer businesses, including blockchain services, hospitality and e-commerce platform.

Darren holds a master’s degree in Electrical Engineering from Boston University, completed the Owner/President Management Program (OPM 63) at Harvard Business School.

Company Bio

OBOOK Holdings Inc. is a global fintech company operating as the OwlTing Group (NASDAQ: OWLS). The Company was founded and is headquartered in Taiwan, with subsidiaries in the United States, Japan, Poland, Singapore, Hong Kong, Thailand, and Malaysia. The Company operates a diversified ecosystem across payments, hospitality, and e-commerce. In 2025, according to CB Insights’ Stablecoin Market Map, OwlTing was ranked among the top 2 global players in the “Enterprise & B2B” category. The Company’s mission is to use blockchain technology to provide businesses with more reliable and transparent data management, to reinvent global flow of funds for businesses and consumers and to lead the digital transformation of business operations. To this end, the Company introduced OwlPay, a Web2 and Web3 hybrid payment solution, to empower global businesses to operate confidently in the expanding stablecoin economy.

For more information, visit https://www.owlting.com/portal/?lang=en.